These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 33903172)

  • 1. HE4 Overexpression by Ovarian Cancer Promotes a Suppressive Tumor Immune Microenvironment and Enhanced Tumor and Macrophage PD-L1 Expression.
    Rowswell-Turner RB; Singh RK; Urh A; Yano N; Kim KK; Khazan N; Pandita R; Sivagnanalingam U; Hovanesian V; James NE; Ribeiro JR; Kadambi S; Linehan DC; Moore RG
    J Immunol; 2021 May; 206(10):2478-2488. PubMed ID: 33903172
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The biomarker HE4 (WFDC2) promotes a pro-angiogenic and immunosuppressive tumor microenvironment via regulation of STAT3 target genes.
    James NE; Emerson JB; Borgstadt AD; Beffa L; Oliver MT; Hovanesian V; Urh A; Singh RK; Rowswell-Turner R; DiSilvestro PA; Ou J; Moore RG; Ribeiro JR
    Sci Rep; 2020 May; 10(1):8558. PubMed ID: 32444701
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor cell-released autophagosomes (TRAPs) promote immunosuppression through induction of M2-like macrophages with increased expression of PD-L1.
    Wen ZF; Liu H; Gao R; Zhou M; Ma J; Zhang Y; Zhao J; Chen Y; Zhang T; Huang F; Pan N; Zhang J; Fox BA; Hu HM; Wang LX
    J Immunother Cancer; 2018 Dec; 6(1):151. PubMed ID: 30563569
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Programmed cell death ligand 1 disruption by clustered regularly interspaced short palindromic repeats/Cas9-genome editing promotes antitumor immunity and suppresses ovarian cancer progression.
    Yahata T; Mizoguchi M; Kimura A; Orimo T; Toujima S; Kuninaka Y; Nosaka M; Ishida Y; Sasaki I; Fukuda-Ohta Y; Hemmi H; Iwahashi N; Noguchi T; Kaisho T; Kondo T; Ino K
    Cancer Sci; 2019 Apr; 110(4):1279-1292. PubMed ID: 30702189
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MRPL15 is a novel prognostic biomarker and therapeutic target for epithelial ovarian cancer.
    Xu H; Zou R; Li F; Liu J; Luan N; Wang S; Zhu L
    Cancer Med; 2021 Jun; 10(11):3655-3673. PubMed ID: 33934540
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Malignant pleural mesothelioma immune microenvironment and checkpoint expression: correlation with clinical-pathological features and intratumor heterogeneity over time.
    Pasello G; Zago G; Lunardi F; Urso L; Kern I; Vlacic G; Grosso F; Mencoboni M; Ceresoli GL; Schiavon M; Pezzuto F; Pavan A; Vuljan SE; Del Bianco P; Conte P; Rea F; Calabrese F
    Ann Oncol; 2018 May; 29(5):1258-1265. PubMed ID: 29514216
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human epididymis protein 4 promotes P‑glycoprotein‑mediated chemoresistance in ovarian cancer cells through interactions with Annexin II.
    Liu Q; Liu DW; Zheng MJ; Deng L; Wang HM; Jin S; Liu JJ; Hao YY; Zhu LC; Lin B
    Mol Med Rep; 2021 Jul; 24(1):. PubMed ID: 33955501
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunotyping in tubo-ovarian high-grade serous carcinoma by PD-L1 and CD8+ T-lymphocytes predicts disease-free survival.
    Bansal A; Srinivasan R; Rohilla M; Rai B; Rajwanshi A; Suri V; Chandra Saha S
    APMIS; 2021 May; 129(5):254-264. PubMed ID: 33455015
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor-associated macrophages and the tumor immune microenvironment of primary and recurrent epithelial ovarian cancer.
    Ojalvo LS; Thompson ED; Wang TL; Meeker AK; Shih IM; Fader AN; Cimino-Mathews A; Emens LA
    Hum Pathol; 2018 Apr; 74():135-147. PubMed ID: 29288043
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Breast cancer cells promote CD169
    Jing W; Guo X; Wang G; Bi Y; Han L; Zhu Q; Qiu C; Tanaka M; Zhao Y
    Int Immunopharmacol; 2020 Jan; 78():106012. PubMed ID: 31865052
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Disruption of tumour-associated macrophage trafficking by the osteopontin-induced colony-stimulating factor-1 signalling sensitises hepatocellular carcinoma to anti-PD-L1 blockade.
    Zhu Y; Yang J; Xu D; Gao XM; Zhang Z; Hsu JL; Li CW; Lim SO; Sheng YY; Zhang Y; Li JH; Luo Q; Zheng Y; Zhao Y; Lu L; Jia HL; Hung MC; Dong QZ; Qin LX
    Gut; 2019 Sep; 68(9):1653-1666. PubMed ID: 30902885
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glycolytic activation of peritumoral monocytes fosters immune privilege via the PFKFB3-PD-L1 axis in human hepatocellular carcinoma.
    Chen DP; Ning WR; Jiang ZZ; Peng ZP; Zhu LY; Zhuang SM; Kuang DM; Zheng L; Wu Y
    J Hepatol; 2019 Aug; 71(2):333-343. PubMed ID: 31071366
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic impact of the tumor immune microenvironment in synovial sarcoma.
    Oike N; Kawashima H; Ogose A; Hotta T; Hatano H; Ariizumi T; Sasaki T; Yamagishi T; Umezu H; Endo N
    Cancer Sci; 2018 Oct; 109(10):3043-3054. PubMed ID: 30133055
    [TBL] [Abstract][Full Text] [Related]  

  • 14. B7-H3 Suppresses Antitumor Immunity via the CCL2-CCR2-M2 Macrophage Axis and Contributes to Ovarian Cancer Progression.
    Miyamoto T; Murakami R; Hamanishi J; Tanigaki K; Hosoe Y; Mise N; Takamatsu S; Mise Y; Ukita M; Taki M; Yamanoi K; Horikawa N; Abiko K; Yamaguchi K; Baba T; Matsumura N; Mandai M
    Cancer Immunol Res; 2022 Jan; 10(1):56-69. PubMed ID: 34799346
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnostic Performance of Serum Human Epididymis Protein 4 (HE4) for Prediction of Malignancy in Ovarian Masses.
    Dewan R; Dewan A; Jindal M; Bhardawaj M
    Asian Pac J Cancer Prev; 2019 Apr; 20(4):1103-1108. PubMed ID: 31030480
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Programmed death ligand-1 over-expression correlates with malignancy and contributes to immune regulation in ovarian cancer.
    Maine CJ; Aziz NH; Chatterjee J; Hayford C; Brewig N; Whilding L; George AJ; Ghaem-Maghami S
    Cancer Immunol Immunother; 2014 Mar; 63(3):215-24. PubMed ID: 24297569
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A multiplex biomarker assay improves the diagnostic performance of HE4 and CA125 in ovarian tumor patients.
    Leandersson P; Åkesson A; Hedenfalk I; Malander S; Borgfeldt C
    PLoS One; 2020; 15(10):e0240418. PubMed ID: 33075095
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ZNF703 promotes tumor progression in ovarian cancer by interacting with HE4 and epigenetically regulating PEA15.
    Wang S; Wang C; Hu Y; Li X; Jin S; Liu O; Gou R; Zhuang Y; Guo Q; Nie X; Zhu L; Liu J; Lin B
    J Exp Clin Cancer Res; 2020 Nov; 39(1):264. PubMed ID: 33246486
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Blockade of TGF-β and PD-L1 by bintrafusp alfa promotes survival in preclinical ovarian cancer models by promoting T effector and NK cell responses.
    Kment J; Newsted D; Young S; Vermeulen MC; Laight BJ; Greer PA; Lan Y; Craig AW
    Br J Cancer; 2024 Jun; 130(12):2003-2015. PubMed ID: 38622286
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical Use of Programmed Cell Death-1 and Its Ligand Expression as Discriminatory and Predictive Markers in Ovarian Cancer.
    Chatterjee J; Dai W; Aziz NHA; Teo PY; Wahba J; Phelps DL; Maine CJ; Whilding LM; Dina R; Trevisan G; Flower KJ; George AJT; Ghaem-Maghami S
    Clin Cancer Res; 2017 Jul; 23(13):3453-3460. PubMed ID: 27986748
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 16.